Maze Therapeutics (NASDAQ:MAZE) Given New $34.00 Price Target at Guggenheim

Maze Therapeutics (NASDAQ:MAZE) had its price target lifted by Guggenheim from $19.00 to $34.00 in a report published on Monday, MarketBeat.com reports. Guggenheim currently has a buy rating on the stock.

MAZE has been the topic of several other research reports. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. HC Wainwright raised their price target on Maze Therapeutics from $34.00 to $50.00 and gave the stock a “buy” rating in a report on Friday. Wedbush began coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price target for the company. Finally, BTIG Research raised their price target on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $32.67.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $23.25 on Monday. The business has a fifty day moving average of $15.50 and a 200 day moving average of $12.35. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $25.50.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth about $66,874,000. Frazier Life Sciences Management L.P. increased its position in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares during the period. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the first quarter worth approximately $45,362,000. Matrix Capital Management Company LP acquired a new position in Maze Therapeutics during the first quarter worth approximately $27,373,000. Finally, Alphabet Inc. acquired a new position in Maze Therapeutics during the first quarter worth approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.